Alpine Global Cuts Immunome Stake to 0.4% as of Dec 31, 2023

TL;DR

**Alpine Global significantly cut its Immunome stake, now holding only 0.4%.**

AI Summary

Alpine Global Management, LLC, a Delaware-based investment firm, filed an Amendment No. 5 to its Schedule 13G on February 12, 2024, disclosing its ownership in Immunome Inc. As of December 31, 2023, Alpine Global Management beneficially owned 192,333 shares of Immunome's common stock, representing 0.4% of the company's outstanding shares. This filing indicates a significant reduction in their stake, as previous filings showed a higher percentage, suggesting a potential shift in their investment strategy for Immunome.

Why It Matters

This reduction in ownership by a notable investment firm could signal a lack of confidence in Immunome's near-term prospects, potentially influencing other investors' decisions.

Risk Assessment

Risk Level: medium — A major institutional investor reducing its stake can be a bearish signal, indicating potential concerns about the company's future performance or valuation.

Analyst Insight

A smart investor would view this reduction in stake by Alpine Global Management, LLC as a potential red flag, prompting further due diligence into Immunome Inc.'s recent performance and future outlook before making any investment decisions.

Key Numbers

• 192,333 — Shares Beneficially Owned (This is the total number of Immunome Inc. common shares Alpine Global Management, LLC reported owning as of December 31, 2023.)
• 0.4% — Percentage of Class (This represents the percentage of Immunome Inc.'s common stock that Alpine Global Management, LLC beneficially owned, indicating a significant reduction from prior filings.)
• December 31, 2023 — Reporting Date (This is the specific date for which the ownership information is reported, providing a clear snapshot of their holdings.)

Key Players & Entities

• Alpine Global Management, LLC (company) — the investment firm filing the SC 13G/A
• Immunome Inc. (company) — the subject company whose shares are being reported
• Delaware (company) — state of incorporation for Alpine Global Management, LLC
• 192,333 (dollar_amount) — number of shares beneficially owned by Alpine Global Management, LLC
• 0.4% (dollar_amount) — percentage of Immunome Inc. common stock beneficially owned
• December 31, 2023 (date) — date of event requiring the filing
• February 12, 2024 (date) — date the filing was made

Forward-Looking Statements

• Immunome Inc.'s stock price may experience downward pressure or increased volatility in the short term. (Immunome Inc.) — medium confidence, target: Q1 2024
• Other institutional investors might re-evaluate their positions in Immunome Inc. following this disclosure. (Institutional Investors) — medium confidence, target: Q2 2024

FAQ

Key Financial Figures

• $0.0001 — , INC. (Name of Issuer) Common stock, $0.0001 par value per share (Title of Class of

Filing Documents

• a021224a.htm (SC 13G/A) — 53KB
• a021224b.htm (EX-99.1) — 2KB
• 0000899140-24-000192.txt ( ) — 56KB

From the Filing

SC 13G/A 1 a021224a.htm SCHEDULE 13G (AMENDMENT NO. 5) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Amendment No. 5 Under the Securities Exchange Act of 1934 IMMUNOME, INC. (Name of Issuer) Common stock, $0.0001 par value per share (Title of Class of Securities) 45257U108 (CUSIP Number) December 31, 2023 (Date of Event which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to which this Schedule is filed: [_] Rule 13d-1(b) [X] Rule 13d-1(c) [_] Rule 13d-1(d) *The remainder of this cover page shall be filled out for a reporting person's initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page. The information required in the remainder of this cover page shall not be deemed to be "filed" for the purpose of Section 18 of the Securities Exchange Act of 1934 ("Act") or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes ). SCHEDULE 13G CUSIP No. 45257U108 1 Names of Reporting Persons Alpine Global Management, LLC 1 2 Check the appropriate box if a member of a Group (see instructions) (a) [ ] (b) [X] 3 Sec Use Only 4 Citizenship or Place of Organization Delaware, USA Number of Shares Beneficially Owned by Each Reporting Person With: 5 Sole Voting Power 192,333 6 Shared Voting Power 0 7 Sole Dispositive Power 192,333 8 Shared Dispositive Power 0 9 Aggregate Amount Beneficially Owned by Each Reporting Person 192,333 10 Check box if the aggregate amount in row (9) excludes certain shares (See Instructions) [ ] 11 Percent of class represented by amount in row (9) 0.45% 12 Type of Reporting Person (See Instructions) OO, Other (Limited Liability Company) 1 In addition to Alpine Global Management, LLC, Alpine Partners (BVI), L.P. also owns the shares indirectly and is a beneficial owner. Item 1. (a) Name of Issuer: IMMUNOME, INC. (b) Address of Issuer's Principal Executive Offices : 665 Stockton Drive, Suite 300 Exton, PA 19341 Item 2. (a) Name of Person Filing: Alpine Global Management, LLC (b) Address of Principal Business Office or, if None, Residence: 140 Broadway, 38 th Floor New York, NY 10005 (c) Citizenship: Delaware, USA (d) Title and Class of Securities: Common stock, $0.0001 par value per share (e) CUSIP No.: 45257U108 Item 3. If this statement is filed pursuant to 240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a: (a) [_] Broker or dealer registered under Section 15 of the Act; (b) [_] Bank as defined in Section 3(a)(6) of the Act; (c) [_] Insurance company as defined in Section 3(a)(19) of the Act; (d) [_] Investment company registered under Section 8 of the Investment Company Act of 1940; (e) [_] An investment adviser in accordance with Rule 13d-1(b)(1)(ii)(E); (f) [_] An employee benefit plan or endowment fund in accordance with Rule 13d-1(b)(1)(ii)(F); (g) [_] A parent holding company or control person in accordance with Rule 13d-1(b)(1)(ii)(G); (h) [_] A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813); (i) [_] A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940; (j) [_] A non-U.S. institution in accordance with Rule 240.13d-1(b)(1)(ii)(J); (k) [_] Group, in accordance with Rule 240.13d-1(b)(1)(ii)(K). If filing as a non-U.S. institution in accordance with Rule 240.13d-1(b)(1)(ii)(J), please specify the type of institution: ____ Item 4 (a) Amount Beneficially Owned: 192,333 (b) Percent of Class: 0.45% Based upon 42,729,847 shares of the registrant's common stock, par value $0.0001 per share, as reported by Immunome, Inc. in its Form 10-Q filed on November 9, 2023 (c) Number of shares as to which such person has: (i) Sole power to vote or to direct the vote: 192,333 (ii) Shared power to vote or to direct the vote: 0 (iii) Sole power to dispose or to direct the disposition of: 192,333 (iv) Shared power to dispose or to direct the disposition of: 0 Item 5. If this statement is being filed to report the fact that as of the date hereof the reporting person has ceased to be the beneficial owner of more than five percent of the class of securities, check the following [ X ]. Item 6. See Exhibit A. Item 7. Identification and classification of the subsidiary which acquired the security being reported on by the parent holding company or control person. N/A Item 8. Identification and classification of members of the group. N/A Item 9. Notice of Dissolution of Group. N/A Item 10. Certifications. By signing below, I certify that, to the best of my knowledge and belief

View Full Filing

View this SC 13G/A filing on SEC EDGAR